First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

Abstract Background Platinum‐based chemotherapy remains a first‐line standard of care for approximately 30% of patients with non‐small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the nab‐paclitaxel/carboplatin (nab‐P/C) combination was shown in the...

Full description

Saved in:
Bibliographic Details
Main Authors: Tobias Dechow, Jorge Riera‐Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke, Dagmar Taeuscher, Manfred Welslau, Karin Potthoff
Format: article
Language:EN
Published: Wiley 2021
Subjects:
carboplatin
Germany
nab‐paclitaxel
non‐small cell lung carcinoma (NSCLC)
real‐world
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/5b6b2c18b24b4eb19418ef882658d450
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/5b6b2c18b24b4eb19418ef882658d450

Similar Items